The European Court of Justice ("ECJ") has issued a ruling that when a directive relating to the
pricing of human medicines requires the removal of a drug from
compulsory health insurance, the directive must explain the
rationale for that decision. According to the ECJ, the obligation
to disclose this information will allow interested parties to
verify whether pricing decisions discriminate between national
medicinal products and those originating in other Member
States.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.